N/A N=38 Brain Connections and Blood Pressure
Hypertension · Mild Cognitive Impairment
Primary: Change in Resting State Network
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=51 Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
Pulmonary Arterial Hypertension
Primary: Change in 6-Minute Walk Distance (6MWD) From Baseline to Week 3 — 11.5 meters
N/A N=25 Resveratrol and Vascular Function in CKD
Chronic Kidney Diseases · Endothelial Dysfunction
Primary: % Change of Brachial Artery Flow-mediated Dilation — 1.3; 0.91 %change
N/A N=103 Visits Versus Telephone Calls for Postoperative Care
Satisfaction · Postoperative Complications · Pelvic Floor Disorder
Primary: Patient Satisfaction — 43; 42; 43; 45 participants
N/A N=221 Text2Breathe: Enhance Parent Communication to Reduce Pediatric Asthma Disparities
Asthma
Primary: Emergency Department Visits for Asthma Care — 1.65; 1.95 ED visits
Phase 2 N=10 Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria
Primary: Percentage of Participants With Reduction in Serum Lactate Dehydrogenase (LDH) Levels Within the First 4 Weeks of LFG316 Treatment as Measured by Response Rate — 10; 0…
N/A N=504 PRIDE. Assessment of the Efficacy, Adherence and Tolerability of the Single Pill Combination Bisoprolol/Perindopril
Coronary Artery Disease · Myocardial Infarction · Arterial Hypertension
Primary: Antihypertensive Effectiveness (SBP and DBP) of Bisoprolol/Perindopril SPC in CAD Patients With Previous MI and HTN at Week 12 of Treatment Compared With Baseline…
Phase 3 N=111 A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Primary: Percentage of Participants With no Change or a Reduction From Baseline in the Number of Gadolinium Enhancing (GdE) Lesions at Month 12 Using Non-responder Imputation…
Phase 2 N=43 A Remotely Delivered Episodic Future Thinking Intervention to Improve Management of Type 2 Diabetes
Type 2 Diabetes
Primary: Change in Glycosylated Hemoglobin — -1.2; -0.30; -1.4; -0.5 percentage of glycosylated hemoglobin — p=.017
Phase 3 N=257 Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)
COPD
Primary: Trough FEV1 on Day 85 — 55.12; -95.78 mL — p=<0.0001
N/A N=91 Dementia With Lewy Bodies - Infinitome
Dementia With Lewy Bodies
Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score
Phase 3 N=455 A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines
Chronic Spontaneous Urticaria
Primary: Mean Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12 (Scenario 1 With UAS7 as Primary Efficacy Endpoint) — -19.41; -11.73 Unit on a scale — p=<…
N/A N=45 Aerobic Training and Non-Exercise Physical Activity
Central Obesity · Obesity
Primary: Change in Waist Circumference — -1.3; -1.9; -4.1 cm — p=0.074
N/A N=162 Posterior Fossa Decompression With or Without Duraplasty for Chiari Type I Malformation With Syringomyelia
Arnold-Chiari Malformation, Type 1 · Chiari Malformation Type I · Type I Arnold-Chiari Malformation
Primary: The Number of Participants With Surgical Complications — 8; 10 Participants
Phase 1 N=32 Pharmacokinetic Study of a Fixed Dose Combination Nefopam Hydrochloride (30 mg) / Paracetamol (500 mg)
Healthy Volunteers
Primary: Nefopam and Paracetamol Pharmacokinetic Profiles in Each Arms After Single Dose — 101.808; 114.957; NA; 118.528 ng/mL